Oncimmune Holdings (GB:ONC) has released an update.
Oncimmune Holdings PLC, a leader in autoantibody profiling for precision medicine, has appointed Cavendish Capital Markets Limited as its Nominated Adviser and Joint Broker. The company, which partners with pharmaceutical and biotech firms to advance targeted therapies, continues to work with Zeus Capital Limited as a Joint Broker. Oncimmune is committed to enhancing drug discovery and development through its expertise in immune system interactions and biomarker discovery.
For further insights into GB:ONC stock, check out TipRanks’ Stock Analysis page.
